Authors

Latest:

Dr. Larkin on Lenvatinib Plus Everolimus in Patients With RCC

James Larkin, MD, PhD, medical oncologist, Royal Marsden Hospital, discusses a phase II study that examined the combination of lenvatinib and everolimus versus either agent alone in patients with renal cell carcinoma.

James Larner, MD

Latest:

Dr. Larner on Integrating Radiation Therapy With Immune Checkpoint Blockade in NSCLC

James Larner, MD, professor and chair of Radiation Oncology, University of Virginia Health System, discusses integrating radiation therapy with immune checkpoint blockade in patients with non–small cell lung cancer (NSCLC).

James M. Cleary MD, PhD

Latest:

BRAF-Mutated Colorectal Cancer: Early Frustrations and Future Optimism

This review highlights that preclinical data and discusses several ongoing clinical trials that are leveraging this information to explore new therapeutic strategies in targeting BRAF-mutated colorectal cancer.

James M. Foran, MD

Latest:

Chronic Myeloid Leukemia: Trial Data From the ASCO and EHA 2023 Annual Meetings

Expert perspectives on key data in chronic myeloid leukemia from the ASCO 2023 and EHA 2023 Annual Meetings.

James M. Reuben, PhD, MBA

Latest:

The Search for Biomarkers in Metastatic Breast Cancer

James M. Reuben, PhD, MBA, discusses the search for biomarkers in patients with metastatic breast cancer.

James M. Rossetti, DO

Latest:

Dr. Rossetti on the Utility of JAK Inhibitors in MPNs

James M. Rossetti, DO, discusses the utility of JAK inhibitors in myeloproliferative neoplasms.

James Melotek, MD

Latest:

Dr. Melotek on Cetuximab Added to Chemotherapy and Chemoradiation in Head and Neck Cancer

James Melotek, MD, Radiation and Cellular Oncology, University of Chicago Medicine, discusses an analysis of a phase II study examining the addition of cetuximab to induction chemotherapy and accelerated or hyperfractionated chemoradiation therapy for locoregionally advanced head and neck cancer.

James Mohler, MD

Latest:

Dr. Mohler on Guidelines for Recording Family History in Prostate Cancer

James Mohler, MD, discusses what information should be included in a family history, based on the updated National Comprehensive Cancer Network guidelines for genetic testing in prostate cancer.

James N. Gerson, MD

Latest:

Dr. Gerson on Clinical Trial Accrual in MCL

James N. Gerson, MD, discusses clinical trial accrual in mantle cell lymphoma.

James N. Kochenderfer, MD

Latest:

Dr. Kochenderfer Discusses the B-cell Antigen CD19

Dr. James Kochenderfer from the National Cancer Institute Discusses the B-cell Antigen CD19

James Natale, PharmD,BCOP, UPMC

James Natale, PharmD, BCOP, UPMC Cancer Center

James O. Armitage, MD

Latest:

The Aggressive Peripheral T-Cell Lymphomas

The aggressive peripheral T-cell lymphomas make up less than 10% of all lymphomas diagnosed each year in the United States.

James P. Allison, PhD

Latest:

Dr. Allison on the Urgency of Drug Development in Oncology

James P. Allison, PhD, discusses his experience with the urgency of drug development in oncology.

James P. Stevenson, MD

Latest:

Maintenance Strategies After Initial Chemotherapy for Non-Small Cell Lung Cancer

James P. Stevenson, MD, discusses optimization of drug and patient selection for maintenance therapies in NSCLC, and how it will continue to be a research focus in today's environment of value-based care.

James R. Berenson, MD

Latest:

Dr. Berenson Discusses Results from the CHAMPION-1 Trial

James R. Berenson, MD, founder, President and Medical and Scientific Director of the Institute for Myeloma and Bone Cancer Research, President of Oncotherapeutics, discusses the dose-escalation portion of the phase I/II CHAMPION-1 study looking at weekly carfilzomib in combination with dexamethasone for patients with relapsed or refractory multiple myeloma.

James R. Berenson, MD, IMBCR

James R. Berenson, MD, Institute for Myeloma

James R. Jett, MD

Latest:

Dr. Jett on Debates on Molecular Testing for Lung Cancer

James R. Jett, MD, professor of Medicine Emeritus, National Jewish Health, discusses the most frequent debates surrounding molecular testing for patients with lung cancer.

James Radke

Latest:

Managing Oral Mucositis in Patients With Cancer

One of the most uncomfortable consequences of anticancer therapy is the development of oral mucositis.